Document Detail

Antiandrogen ICI 176,334 does not prevent development of androgen insensitivity in S115 mouse mammary tumour cells.
MedLine Citation:
PMID:  2214758     Owner:  NLM     Status:  MEDLINE    
Many forms of endocrine therapy for steroid-sensitive tumours involve regimes of steroid agonist deprivation by administration of steroid antagonists. The partial or short-lived response to such therapy results from the inevitable progression of the tumour cells to a state of steroid insensitivity. Several cell culture systems have shown that steroid ablation results in loss of steroid sensitivity and we have used an in vitro model here to study the influence of steroid antagonists on this progression. Growth of androgen-responsive S115 mouse mammary tumour cells in the long-term absence of steroid results in a loss of androgen-sensitivity. We have studied here the effects of the pure antiandrogen ICI 176,334 on the growth of S115 cells and on their progression to steroid autonomy. Although a pure antiandrogen in its action on these cells with very low toxicity, it had no protective effect against loss of cellular or molecular androgen-responsive parameters. The clinical implications for endocrine therapy are discussed.
P D Darbre; R J King
Related Documents :
6673428 - Isolation and characterization of elongation factor ef-2 from guerin tumour.
6553508 - Antibodies to tumour eluates react preferentially with non-lymphoid tumours.
8105838 - A cross-linking assay allows the detection of receptors for the somatostatin analogue, ...
18243718 - Pyruvate kinase isoenzyme m2 is not of diagnostic relevance as a marker for oral cancer.
1280208 - Dopaminergic regulation of the gt1 gonadotropin-releasing hormone (gnrh) neuronal cell ...
3405278 - Lipid composition and effect of amphotericin b on yeast cells of paracoccidioides brasi...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of steroid biochemistry     Volume:  36     ISSN:  0022-4731     ISO Abbreviation:  J. Steroid Biochem.     Publication Date:  1990 Aug 
Date Detail:
Created Date:  1990-11-21     Completed Date:  1990-11-21     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0260125     Medline TA:  J Steroid Biochem     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  385-9     Citation Subset:  IM    
Cellular Endocrinology Laboratory, Imperial Cancer Research Fund, London, England.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Androgen Antagonists / pharmacology*
Anilides / pharmacology*
Blotting, Northern
Cell Division / drug effects*
Cell Line
DNA, Neoplasm / genetics,  isolation & purification
Mammary Neoplasms, Experimental
RNA, Neoplasm / genetics,  isolation & purification
Restriction Mapping
Testosterone / pharmacology*
Tosyl Compounds
Reg. No./Substance:
0/Androgen Antagonists; 0/Anilides; 0/DNA, Neoplasm; 0/Nitriles; 0/RNA, Neoplasm; 0/Tosyl Compounds; 58-22-0/Testosterone; 90357-06-5/bicalutamide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  AV nodal reentrant tachycardia.
Next Document:  Hydroxylated triphenylacrylonitriles adopt a unique orientation within the binding site of the estro...